Neurosciences

Overview

The Neuroscience area is consolidating its position as one of the largest clusters of research labs working on neurological diseases across Europe. At present, the area comprises 14 groups with more than one hundred fully dedicated researchers in close contact with top clinicians in the hospital. These research groups pursue a better and multifaceted understanding of the etiopathogenic mechanisms underlying a large variety of mostly adult but also pediatric neurological disorders including stroke, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease, primary headaches, epilepsy, neuromuscular disorders, and also neurosurgical and psychiatric pathologies. The area also integrates groups involved in neuroimaging, analysis and interpretation of high-throughput data, and gene therapy strategies to target inflammatory and neurodegenerative neurological conditions.

Publications

316

total

1898

impact factor

6.01

average impact factor

Group Leader: Raúl Juntas Morales

team

group-zoom

zoom

group-download

download

The main research lines of the group have continued to be focused on the genetic factors influencing the amyotrophic lateral sclerosis (ALS) and myasthenia gravis (MG) phenotypes. In addition, with the new leadership of Dr. Raúl Juntas Morales, research lines have been extended to study other neuromuscular diseases such as titinopathies, calpainopathies and other kind of rare myopathies.

A new project testing the neuroinflammatory hypothesis in ALS has been started using HLA genes high-resolution genotyping and analysis of their expression in the CNS. We have also started a new medical translational research line identifying biomarkers for ALS progression.

The group has published the results of clinical studies using new ALS treatments (biotin, aldesleukin) and the identification of vitamin D and serum neurofilament as a prognostic biomarker of ALS severity and survival.

The group has identified new genetic risk factors in HLA and ENOX1 genes in Spanish MG patients (PhD thesis of Dr. Maria Salvadó).

1

total

3

impact factor

3^.29

average impact factor

SELECTED ARTICLES

Villar-Quiles RN, Catervi F, Cabet E, Juntas-Morales R, Genetti CA, Gidaro T, Koparir A, Yüksel A, Coppens S, Deconinck N, Pierce-Hoffman E, Lornage X, Durigneux J, Laporte J, Rendu J, Romero NB, Beggs AH, Servais L, Cossée M, Olivé M, Böhm J, Duband-Goulet I, Ferreiro A.
ASC-1 Is a Cell Cycle Regulator Associated with Severe and Mild Forms of Myopathy.
Ann Neurol. 2020;87(2):217-232.
DOI: 10.1002/ana.25660
IF: 9.037
Cerino M, Campana-Salort E, Salvi A, Cintas P, Renard D, Juntas Morales R, Tard C, Leturcq F, Stojkovic T, Bonello-Palot N, Gorokhova S, Mortreux J, Maues De Paula A, Lévy N, Pouget J, Cossée M, Bartoli M, Krahn M, Attarian S.
Novel CAPN3 variant associated with an autosomal dominant calpainopathy.
Neuropathol Appl Neurobiol. 2020;46(6):564-578.
DOI: 10.1111/nan.12624
IF: 7.500
Thouvenot E, Demattei C, Lehmann S, Maceski-Maleska A, Hirtz C, Juntas-Morales R, Pageot N, Esselin F, Alphandéry S, Vincent T, Camu W.
Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis.
Eur J Neurol. 2020;27(2):251-257.
DOI: 10.1111/ene.14063
IF: 4.516
Juntas Morales R, Perrin A, Rivier F, Cances C, Walther-Louvier U, Van Goethem C, Thèze C, Lacourt D, Pégeot H, Zenagui R, Uro-Coste E, Leboucq N, Malfatti E, Delaby C, Lehmann S, Rigau V, Koenig M, Cossée M.
The importance of an integrated genotype-phenotype strategy to unravel the molecular bases of titinopathies.
Neuromuscul Disord. 2020;30(11):877-887.
DOI: 10.1016/j.nmd.2020.09.032
IF: 3.115
Juntas-Morales R, Pageot N, Marin G, Dupuy AM, Alphandery S, Labar L, Esselin F, Picot MC, Camu W.
Low 25OH Vitamin D Blood Levels Are Independently Associated With Higher Amyotrophic Lateral Sclerosis Severity Scores: Results From a Prospective Study.
Front Neurol. 2020;11:363.
DOI: 10.3389/fneur.2020.00363
IF: 2.889

View all publications